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Enhanced Permeability and Binding Activity of
Isobutylene-Grafted Peptides
Shuang Sun,[a] Ismael CompaÇjn,[b] Nuria Mart&nez-S#ez,[a] Jo¼o D. Seixas,[c]
Omar Boutureira,[a] Francisco Corzana,*[b] and GonÅalo J. L. Bernardes*[a, c]
We present a new peptide-macrocyclization strategy with an
isobutylene graft. The reaction is mild and proceeds rapidly
and efficiently both for linear and cyclic peptides. The resulting
isobutylene-grafted peptides possess improved passive mem-
brane permeability due to the shielding of the polar backbone
of the amides, as demonstrated by NMR spectroscopy and mo-
lecular dynamics simulations. The isobutylene-stapled struc-
tures are fully stable in human plasma and in the presence of
glutathione. This strategy can be applied to bioactive cyclic
peptides such as somatostatin. Importantly, we found that
structural preorganization forced by the isobutylene graft
leads to a significant improvement in binding. The combined
advantages of directness, selectivity, and smallness could allow
application to peptide macrocyclization based on this attach-
ment of the isobutylene graft.
Intramolecular side-chain-to-side-chain crosslinking, commonly
termed “stapling” or “macrocyclization”,[1] is an important tech-
nology in the development of bioactive peptide-based thera-
peutics. Linear peptides are often easily degraded by proteas-
es, and possess low binding affinity and cell permeability.[2]
Macrocyclization has evolved as a promising approach to tack-
ling these problems. The cyclized structure often shows en-
hanced biophysical properties, cellular uptake, and binding af-
finity of peptides while maintaining high specificity for its bio-
logical targets.[3] Over the past decades, the chemical toolbox
available for macrocyclization has expanded greatly, and now
includes disulfide bond formation,[4] lactam formation,[5] ring-
closing metathesis,[1, 6] and cycloaddition.[7] Proteinogenic cys-
teine has attracted significant interest as a convenient handle
for stapling, owing to the high nucleophilicity of the thiolate
and its unique reactivity.[3a] Chemical approaches for cysteine
stapling include S-alkylation,[8] SN-arylation,
[9] tetrazine sta-
pling,[10] and radical thiolene[11] reactions. Among the cysteine-
stapling methods, S-alkylation is the most flexible approach, as
a wide range of bis-thiol-reactive linkers is commercially avail-
able. The first investigation of thiol-reactive linkers by using
1,3,5-tris(bromomethyl)benzene was reported in 1985,[12] fol-
lowed by that of its bis-reactive analogues, 1,2- and 1,3-bis-
(bromomethyl)benzene.[13] In recent years, this strategy has
also been successfully applied in peptide drug development.[14]
Despite the many tools available for peptide macrocyclization,
discovering suitable grafts that yield membrane-permeable
cyclic peptides with enhanced binding affinities remains a
great challenge.
Cysteine residues are easily incorporated into the peptide
sequence through solid-phase peptide synthesis. This facile
incorporation is an important advantage over other stapling
approaches based on nonproteinogenic amino acids. One chal-
lenge associated with cysteine macrocyclization strategies is
potential oxidation to form disulfides. Thus, an efficient strat-
egy for cysteine stapling should, in principle, be compatible
with the presence of reducing agents in a mild, one-pot reac-
tion. Concurrently, the graft should be both small and biologi-
cally inert. Here, we described a new cysteine crosslinking
strategy that allows the biocompatible and chemoselective in-
stallation of a small, rigid isobutylene graft (Scheme 1).
Our investigation commenced with a linear pentamer model
peptide CAAAC (peptide I, Scheme 2), which had cysteines at
the i and i+4 positions, prepared by Fmoc-based solid-phase
peptide synthesis (SPPS). Tris(2-carboxyethyl) phosphine (TCEP)
was added to prevent formation of the disulfide, followed by
Scheme 1. Schematic representation of the macrocyclization of peptides
with cysteine residues by using bis-electrophilic isobutylene.
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the addition of stapling reagent 1; this afforded exclusively the
stapled peptide CAAAC I’ in 71% yield. The same procedure
was then applied successfully to other hepta- and octamer
linear peptides with different sequence compositions that con-
taining cysteines at the i,i+6 or i,i+7 positions (Scheme 2). In
each case, the linear peptides afforded the desired cyclic deriv-
atives in high conversion and yield at room temperature. Final-
ly, because the double bond of the isobutylene graft could po-
tentially be used as a handle for further conjugation, we evalu-
ated its reactivity under thiolene and inverse-electron-demand
Diels–Alder conditions. We found that, under the conditions
tested, the alkene did not act as a partner for either thiolene
or inverse electron demand Diels–Alder (data not shown). This
is a significant difference compared to the method described
by Dawson and co-workers,[8c] in which the introduced moiety
can be used for further conjugation. On the other hand, the
isobutylene scaffold is more flexible than the bis(bromometh-
yl)benzene platform used in the CLIPS strategy;[8b] in some
cases this could be a competitive advantage for selecting the
bioactive conformation.
Next, we determined the structural changes induced by the
incorporation of the isobutylene staple into the large (i,i+7)
peptide IV by combining NMR spectroscopy and molecular dy-
namics (MD) simulations. The 2D ROESY spectra showed sub-
stantial differences between the unstapled and stapled peptide
in terms of their conformational preferences (Figure 1A and B,
Supporting information). Clear medium-sized NH–NH NOE
crosspeaks, which are characteristic of a predominantly folded
conformation in solution, were observed for stapled peptide
IV’; the absence of these NH–NH NOE crosspeaks for unstapled
peptide IV is in agreement with an extended disposition of the
backbone.[15] To obtain an experimentally derived conforma-
tional ensemble of compounds IV and IV’, 20-ns MD simula-
tions with time-averaged restraints (MD-tar)[16] were carried out
in explicit water with the key experimental distances included
as restraints. The MD-tar simulations were performed by using
the AMBER 16[17] package with parm14SB and GAFF force
fields.[18] The good agreement found between the experimen-
tal and theoretical distances validates the outcome of the MD-
tar calculations (see the Supporting Information). According to
these calculations, peptide IV is reasonably flexible in solution,
presenting a random-coil distribution for its backbone. Con-
versely, stapled peptide IV’ is rather rigid, showing a folded
backbone held by the isobutylene staple (Figure 1C and D,
Supporting Information).
Scheme 2. Macrocyclization of linear peptides with cysteines at the (i,i+4),
(i,i+6) and (i,i+7) positions.
Figure 1. Conformation analysis of stapled and unstapled peptides in solu-
tion. Sections of the 500 ms ROESY spectra (400 MHz) of peptides A) IV and
B) IV’ in H2O/D2O (9:1) at pH 6.5 and 20 8C, showing amide–aliphatic cross-
peaks. Structural ensembles obtained for C) peptide IV and D) stapled pep-
tide IV’ through 20-ns MD-tar simulations. The backbone is shown in green,
and the carbon atoms of isobutylene moiety are in purple. The numbers
indicate the rmsd for heavy-atom superimposition of the backbone with
respect to the average structure. E) PSA estimated for peptides IV and IV’
through the MD-tar simulations.
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We then estimated the solvent-exposed polar surface area
(PSA) of peptides IV and IV’ through the MD simulations. The
stapled peptide IV’ displayed around 15% less PSA than the
unstapled variant IV; this suggests that the folded conforma-
tion forced by the isobutylene fragment promotes shielding of
the polar backbone amides (Figure S26). We then decided to
determine the passive membrane permeability of peptides II–
IV and their stapled variants experimentally, a key feature for
the development of peptide-based therapeutics (Table 1).[19] All
the isobutylene-grafted peptides had a significant improve-
ment in permeability compared to their linear forms, particu-
larly compound IV’. For all stapled derivatives, we observed
values of @logPe<5.0; this is indicative of highly passively per-
meable compounds.[20] These data highlight the practicability
of the method for developing bioactive peptides with favora-
ble properties.
The feasibility of our stapling approach in aqueous solution,
and the impact of the isobutylene scaffold on bioactivity were
evaluated further with somatostatin. This peptide inhibits the
release of growth hormone, insulin and glucagon, and possess-
es a disulfide bond between two cysteines at the i and i+11
positions.[21] Unlike the disulfide bond, which is sensitive to the
biological environment, especially in the presence of biological
thiols, the stapled form with the isobutylene graft can improve
pharmacokinetics and binding affinity. The reaction was con-
ducted in water with 10% DMF as co-solvent, and afforded the
stapled somatostatin quantitatively (Figure 2A). This is possible
because our method is compatible with TCEP and can be per-
formed in one pot. Notably, the stapled somatostatin was fully
stable in the presence of glutathione and human plasma at
37 8C for 48 h (Figures S20 and S21). The affinity of the peptide
for the somatostatin receptor type 2 (SSTR2) was experimental-
ly determined by tryptophan fluorescence spectroscopy.[22] As
shown in Figure 2B, the fluorescence emission peak of pure
SSTR2 solution was at 328 nm. After increasing the concentra-
tion of either native or stapled somatostatin, the emission
peak of both solutions shifted to 338 nm, with a decrease in
intensity. Subsequent addition of somatostatin did not cause
any shift in either peak, thus indicating the saturation of
SSTR2. The minimum concentration of the somatostatin surro-
gate required to achieve saturation was 3.5 mm ; in contrast, at
least 5.5 mm of the native somatostatin was needed. These
data suggest that the isobutylene-grafted somatostatin has a
higher binding affinity for SSTR2. This improvement in binding
activity represents a considerable advantage of the incorpora-
tion of the isobutylene graft when compared to other three-
carbon grafts, such as the recently reported methylene thio-
acetal, which led to a decrease in affinity for SSTR2.[8e] Our 0.5-
ms unrestrained MD simulations performed on both derivatives
indicated that the stapled somatostatin is more rigid in solu-
tion (Figure 2C). Although the circular dichroism (CD) spectra
Table 1. The parallel artificial membrane permeability assay (PAMPA).[a]
Compound Permeability @logPe Compound Permeability @logPe
[nms@1] [nms@1]
II 7.6 5.12 II’ 12 4.96
III <0.01 III’ 10 4.99
IV 6.0 5.22 IV’ 13 4.90
[a] Permeability was measured at pH 7.4 and at room temperature, the
value is reported as an average of quadruplicates.
Figure 2. Stapling as well as structural and biological evaluation of somatostatin. A) Schematic representation of the stapling of somatostatin ; B) Tryptophan
fluorescence spectroscopy of somatostatin. Blue: 1 mm SSTR2 in buffer; purple: 5.5 mm native somatostatin and 1 mm SSTR2 in buffer; green: 3.5 mm stapled
somatostatin and 1 mm SSTR2 in buffer. C) Structural ensembles obtained for native and stapled somatostatin through 0.5-ms unrestrained MD simulations.
The atomic fluctuation (Ca) analysis of both peptides is also shown. The data correspond to the average structure of both molecules throughout the simula-
tions. The backbone is shown in green, and carbon atoms of cysteine isobutylene residues are in purple. The numbers indicate the rmsd for heavy-atom su-
perimposition of the backbone with respect to the average structure. D) CD spectra of native and stapled somatostatin.
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of somatostatin and the corresponding stapled peptide (Fig-
ure 2D and the Supporting Information) are rather similar, the
peak at 225 nm found in somatostatin might be indicative of
the presence of a higher degree of polyproline (PPII) conforma-
tion for this peptide.[23] MD simulations showed the S@S dis-
tance in the isobutylene scaffold to be around 4.2:0.4 a—
larger than the conventional S@S disulfide bond length (ca.
2.0 a) and the S@S distance in methylene thioacetals (close to
3.0 a) ;[8e] hypothetically this would allow the required degree
of flexibility to adopt a bioactive conformation. The restrained
peptide flexibility and structural preorganization within the
backbone, favored by the formation of intramolecular hydro-
gen bonds, might reduce the entropy cost of receptor binding
that limits the conformational ensemble and, ultimately, in-
crease the binding affinity compared to those of disulfide cy-
clized analogues.[24]
In conclusion, we have demonstrated a robust cysteine mac-
rocyclization and stapling strategy in which an isobutylene
graft is introduced in a one-pot (with TCEP), biocompatible
manner. This method was applied to several linear peptides of
various sequence composition and a bioactive disulfide cyclic
peptide. The shielding of the polar backbone of the amides
promoted by the isobutylene graft led to highly membrane-
permeable peptide macrocycles. Enhanced binding activity, re-
sulting from limited flexibility and structural preorganization of
the peptide backbone, was also observed. We believe that this
access to such a “small” site-selectively introduced isobutylene,
which is less disruptive than many current bulky grafts, as
demonstrated here for linear and cyclic peptides, is likely to
find significant use for the peptide drug discovery community
by allowing access to structures with improved properties.
Experimental Section
General procedure for peptide stapling with isobutylene: The
linear peptide (0.02 mmol) was dissolved in DMF (10 mL). K2CO3
(0.10 mmol) and tris(2-carboxyethyl)phosphine (TCEP; 0.02 mmol)
were then added. The solution was stirred for 1 h at room temper-
ature. 3-Bromo-2-(bromomethyl)prop-1-ene (0.025 mmol) was then
added, and the mixture was stirred for an additional 12 h. The
crude peptide was purified by reversed-phase HPLC to obtain the
corresponding stapled derivative. In all cases the yield was +75%.
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